Clinical Scorecard: At-Home Brain Stimulation for Alzheimer’s
At a Glance
| Category | Detail |
|---|---|
| Condition | Alzheimer Disease (AD) |
| Key Mechanisms | Gamma transcranial alternating current stimulation (tACS) targeting the precuneus to modulate brain activity. |
| Target Population | Patients with prodromal or mild Alzheimer disease, biomarker-confirmed. |
| Care Setting | Home-based treatment. |
Key Highlights
- Home-based gamma tACS was well tolerated with high adherence (fewer than 2% missed sessions).
- Active stimulation showed significant improvements in global cognitive function and associative memory compared to sham.
- No serious adverse events reported; the most common adverse effect was transient light flickering.
- Neurophysiologic measures indicated increased gamma-frequency activity post-stimulation.
- Plasma biomarkers did not show significant changes during the study.
Guideline-Based Recommendations
Diagnosis
- Biomarker confirmation of Alzheimer disease is essential.
Management
- Consider home-based gamma tACS for cognitive modulation in research settings.
Monitoring & Follow-up
- Monitor cognitive function and neurophysiologic measures during treatment.
Risks
- Transient light flickering reported; no serious adverse events.
Patient & Prescribing Data
50 patients with biomarker-confirmed Alzheimer disease, mean age 67 years.
Active treatment showed cognitive improvements; no added benefit beyond 8 weeks.
Clinical Best Practices
- Encourage adherence to home-based stimulation protocols.
- Evaluate cognitive and neurophysiologic outcomes regularly.
- Consider caregiver burden in treatment planning.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
